

Advances In Therapy®

November/December 1995 Volume 12 No. 6

*The International Journal of
Drug, Device & Diagnostic Research*

UW PHARMACY LIBRARY

CONTENTS

S. H. Mandy: Chest and Back Acne: A Retrospective Review	321
S. M. H. Qadri, Y. Ueno, P. Domenico, B. A. Cunha: Activity of Ticarcillin/Clavulanic Acid Against Gram-Negative Nosocomial Isolates	333
M. A. Drouin, W. H. Yang, F. Horak, P. H. van de Heyning, G. H. Kunkel, C. I. Backhouse, M. R. Danzig: Adding Loratadine to Topical Nasal Steroid Therapy Improves Moderately Severe Seasonal Allergic Rhinoconjunctivitis	340
B. Wiita, J. G. Young, L. J. Downey: Esterified Estrogens or Estrogen Plus Androgen: Effective Postmenopausal Hormone-Replacement Therapy	350
A. H. Agha, J. B. Roy, D. J. Culkin, K. Lyon: The Impact of 5-Alpha-Reductase Inhibitors on the Number of Prostatectomies for Benign Prostatic Hyperplasia	361
Index	367

HCI
HEALTH
COMMUNI-
CATIONS
INC

Advances In Therapy®

The International Journal of
Drug, Device & Diagnostic Research

Publication Staff

Joel L. Shapiro Publisher	Glenn S. Shapiro Associate Publisher
Katherine Zsoldos Senior Editor	Danuta T. Arcyz Production Manager
Naomi F. Westheim Copy Editor	Gilbert Velazquez Creative/Art Director

Advances In Therapy® was founded on the concept that the reporting and publication of research studies and programs must be accelerated. The editors of the journal are committed to acknowledgment of all submitted articles within *one week* of receipt, medical review of all articles within *two weeks*, and publication of acceptable papers within *six to eight weeks*, providing authors conform to copy-reading schedules.

The journal is published bimonthly and is dedicated to the timely publication of studies in clinical medicine and scientific research, case reports, review articles, and other original contributions in the areas of drug therapy, diagnosis, instrumentation, and other related fields, as well as proceedings of symposia and special topics. The journal is distributed on subscription to physicians, other health professionals, health product manufacturers, libraries, and those with related interests.

***Advances In Therapy*® is indexed and abstracted by Current Contents/Clinical Medicine, SciSearch, Research Alert, International Pharmaceutical Abstracts, and Excerpta Medica, and is listed in BIOSIS data base.**

Change of Address

POSTMASTER: Send changes of address to *Advances In Therapy*®, Health Communications Inc., 20 Highland Avenue, Suite 6, Metuchen, NJ 08840-1949.

Copyright Notice

Authorization to photocopy items for internal or personal use is granted by Health Communications Inc., publishers of *Advances In Therapy*®, provided that the base fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged.

The articles in this publication are the opinions of the authors; the journal assumes no responsibility for any of the statements or data presented herein.

Editorial Style

See Information for Contributors in this issue or write to the journal for details.

Subscription Rates

\$60 for one year (six issues); for airmail delivery outside the continental U.S. add \$50. Subscriptions may begin at any time. Most back issues are available. Complete volumes available except for Volume 5.

Editorial Office

Correspondence and inquiries regarding the journal should be addressed to: Health Communications Inc., 20 Highland Avenue, Suite 6, Metuchen, NJ 08840-1949; telephone (908) 548-9130; facsimile (908) 548-8555.

Support

Advances In Therapy® carries no product advertising matter. Subsidization is based on subscriptions and assistance in support of publication costs. Quotations for reprint orders will be furnished promptly.

Advances In Therapy®

November/December 1995 Volume 12 No. 6

CONTENTS

S. H. Mandy: Chest and Back Acne: A Retrospective Review	321
S. M. H. Qadri, Y. Ueno, P. Domenico, B. A. Cunha: Activity of Ticarcillin/Clavulanic Acid Against Gram-Negative Nosocomial Isolates	333
M. A. Drouin, W. H. Yang, F. Horak, P. H. van de Heyning, G. H. Kunkel, C. I. Backhouse, M. R. Danzig: Adding Loratadine to Topical Nasal Steroid Therapy Improves Moderately Severe Seasonal Allergic Rhinoconjunctivitis	340
B. Wiita, J. G. Young, L. J. Downey: Esterified Estrogens or Estrogen Plus Androgen: Effective Postmenopausal Hormone-Replacement Therapy	350
A. H. Agha, J. B. Roy, D. J. Culkin, K. Lyon: The Impact of 5-Alpha-Reductase Inhibitors on the Number of Prostatectomies for Benign Prostatic Hyperplasia	361
Index	367

HCI
HEALTH
COMMUNI-
CATIONS
INC.

Adding Loratadine to Topical Nasal Steroid Therapy Improves Moderately Severe Seasonal Allergic Rhinoconjunctivitis

Michel A. Drouin, M.D.

William H. Yang, M.D.

Section of Allergy and Clinical
Immunology

Ottawa Civic Hospital

University of Ottawa

Ottawa, Canada

Friedrich Horak, M.D.

HNO University Clinic

University of Vienna

Vienna, Austria

Paul H. van de Heyning, M.D.

Department of ENT and Head
and Neck Surgery

University Clinic of Antwerp

Antwerp, Belgium

Gert H. Kunkel, M.D.

Department of Clinical Immunology
and Asthma O.P.D.

University Clinic Charlottenburg of
the Free University of Berlin

Berlin, Germany

Charles I. Backhouse, M.D.

The Medical Centre

East Horsley, Surrey, England

Melvyn R. Danzig, Ph.D.

Schering-Plough Research Institute

Kenilworth, New Jersey

ABSTRACT

This study assessed the efficacy of adding the nonsedating selective H₁ antihistamine loratadine to topical intranasal beclomethasone dipropionate (BDP)

©1995 Health Communications Inc.
Transmission and reproduction of this material in whole
or part without prior written approval are prohibited.

0422

Address reprint requests to
Melvyn R. Danzig, Ph.D.
Schering-Plough Research Institute
2015 Galloping Hill Road
Kenilworth, NJ 07033-0539

to treat patients with seasonal allergic rhinoconjunctivitis (SAR). In a double-blind, randomized, parallel-group trial, 154 patients, ages 18 to 65, with moderately symptomatic SAR were treated with intranasal BDP (100 µg in each nostril twice daily) combined with 10 mg of loratadine or placebo for 7 days. Four nasal and four non-nasal symptoms were evaluated following 3 and 7 days of treatment, and patients recorded daily symptoms and possible adverse effects in a diary. BDP alone improved the symptoms of SAR; however, BDP plus loratadine provided further improvement. Patients treated with BDP plus loratadine achieved significantly greater ($P<.05$) relief of both nasal and non-nasal symptoms than those treated with BDP plus placebo. No differences were noted in the incidence or type of adverse effects in the two treatment groups. Loratadine plus topical intranasal BDP controls SAR more effectively than does BDP alone, without any increase in adverse effects.

Keywords: antihistamine; topical corticosteroid; loratadine; beclomethasone dipropionate; allergic rhinitis

INTRODUCTION

Current pharmacologic management of rhinitis provides less than complete relief of symptoms and may be associated with variable degrees of adverse effects.¹ Because many of the drugs currently available affect different components of the allergic response, combinations of drugs with complementary effects can maximize therapeutic efficacy.

Loratadine is an orally effective and long-acting antihistamine.² It has a high selectivity for peripheral histamine H₁ receptors and a low affinity for central nervous system H₁, cholinergic, or alpha-adrenergic receptors in vitro or in vivo.^{3,4} Loratadine does not readily cross the blood-brain barrier and has an incidence of sedation equal to that of placebo.⁵ Loratadine is rapidly absorbed, with peak concentrations in serum reached within 2 hours, an effect consistent with its rapid onset of action.⁶ Loratadine relieves most of the symptoms related to SAR² and is as effective as terfenadine,⁷⁻⁹ astemizole,^{10,11} and cetirizine.¹²

The nasal response to allergen challenge can be divided into an early reaction (occurring within minutes of allergen exposure) and a late-phase reaction (occurring 4 to 10 hours after allergen challenge in about half of patients). A rechallenge reaction may occur with a second exposure to allergen 10 hours after the first challenge, resulting in increased symptoms and associated physiologic effects.¹³ Systemic corticosteroids reduce symptoms and mediator release in the late and rechallenge phases of the process but have little effect on the early phase. Intranasally applied steroids are effective in all three phases of the response, however.^{1,14} Studies on their mode of action have shown that they reduce the number of eosinophils, the presence of eosinophil cationic protein, and the number of mast-cell progenitors in the nasal mucosa.¹

Topical steroids, including BDP, flunisolide, budesonide, triamcinolone acetate, fluticasone propionate, and mometasone furoate, are efficacious agents for all the nasal symptoms of SAR.¹ H₁-receptor antagonists relieve the ocular symptoms that

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.